Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 01/15 11:01:50 am
7572 GBX   +0.17%
07:36aSouth Africa's mining industry to support COVID-19 vaccine rollout
RE
07:28aASTRAZENECA : Nepal clears AstraZeneca vaccine for emergency use
AQ
06:00aASTRAZENECA : Buy rating from Deutsche Bank
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.
Strengths
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 42% by 2022.
  • The company returns high margins, thereby supporting business profitability.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • The company's enterprise value to sales, at 4.26 times its current sales, is high.
  • The company benefits from high valuations in earnings multiples.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ASTRAZENECA PLC3.21%135 863
JOHNSON & JOHNSON2.08%422 918
ROCHE HOLDING AG0.99%301 476
NOVARTIS AG-0.16%214 006
MERCK & CO., INC.0.45%207 893
PFIZER INC.-0.16%204 271
ABBVIE INC.4.18%197 080
ELI LILLY AND COMPANY10.57%169 250
NOVO NORDISK A/S2.48%165 077
BRISTOL-MYERS SQUIBB COMPAN..6.43%149 189
AMGEN INC.5.11%140 687
SANOFI2.88%123 562
GLAXOSMITHKLINE PLC3.83%95 210
CHUGAI PHARMACEUTICAL CO., ..5.43%91 993
JIANGSU HENGRUI MEDICINE CO..-1.15%90 348
DAIICHI SANKYO COMPANY, LIM..3.17%68 027
More Results
Financials (USD)
Sales 2020 26 397 M - -
Net income 2020 2 992 M - -
Net Debt 2020 13 217 M - -
P/E ratio 2020 43,1x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,64x
EV / Sales 2021 4,90x
Nbr of Employees 70 600
Free-Float 95,7%
Upcoming event on ASTRAZENECA PLC
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes